Abbott Labs (ABT) Gets FDA Approval for FreeStyle Libre 3 - BofA Securities
Tweet Send to a Friend
BofA Securities analyst Travis Steed reiterated a Buy rating and $140.00 price target on Abbott Labs (NYSE: ABT) after the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
